-
Je něco špatně v tomto záznamu ?
L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB
J. Klat, A. Mladenka, J. Dvorackova, S. Bajsova, O. Simetka,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- buněčná adheze MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- endometroidní karcinom epidemiologie genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru epidemiologie genetika patologie MeSH
- molekula buněčné adheze nervové L1 genetika MeSH
- nádorové biomarkery genetika MeSH
- nádory endometria epidemiologie genetika patologie MeSH
- prognóza MeSH
- progrese nemoci MeSH
- regulace genové exprese u nádorů MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IA-IB endometrial cancer. MATERIALS AND METHODS: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87.2%) were available for L1CAM analysis by immunohistochemistry. RESULTS: Of the 312 tumor samples analyzed, 93 (29.8%) were L1CAM-positive. L1CAM positivity was significantly more common in grade 3 compared to grade 1-2 carcinomas (p=0.02). Patients with L1CAM positivity more commonly experienced disease progression. Distant metastasis was significantly associated with L1CAM positivity (p=0.01). Progression-free interval and overall survival did not significantly differ between L1CAM-positive and L1CAM-negative cases. CONCLUSION: L1CAM is a promising independent prognostic marker associated with aggressive tumor behavior and recurrence risk, but not with overall survival.
Department of Obstetrics and Gynecology University Hospital Ostrava Ostrava Poruba Czech Republic
Institute of Pathology University Hospital Ostrava Ostrava Poruba Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012003
- 003
- CZ-PrNML
- 005
- 20190409153615.0
- 007
- ta
- 008
- 190405s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.13128 $2 doi
- 035 __
- $a (PubMed)30591489
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Klat, Jaroslav $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic jaroslav.klat@fno.cz.
- 245 10
- $a L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB / $c J. Klat, A. Mladenka, J. Dvorackova, S. Bajsova, O. Simetka,
- 520 9_
- $a AIMS: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IA-IB endometrial cancer. MATERIALS AND METHODS: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87.2%) were available for L1CAM analysis by immunohistochemistry. RESULTS: Of the 312 tumor samples analyzed, 93 (29.8%) were L1CAM-positive. L1CAM positivity was significantly more common in grade 3 compared to grade 1-2 carcinomas (p=0.02). Patients with L1CAM positivity more commonly experienced disease progression. Distant metastasis was significantly associated with L1CAM positivity (p=0.01). Progression-free interval and overall survival did not significantly differ between L1CAM-positive and L1CAM-negative cases. CONCLUSION: L1CAM is a promising independent prognostic marker associated with aggressive tumor behavior and recurrence risk, but not with overall survival.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a endometroidní karcinom $x epidemiologie $x genetika $x patologie $7 D018269
- 650 _2
- $a buněčná adheze $7 D002448
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a nádory endometria $x epidemiologie $x genetika $x patologie $7 D016889
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x epidemiologie $x genetika $x patologie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a molekula buněčné adheze nervové L1 $x genetika $7 D039842
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mladenka, Ales $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.
- 700 1_
- $a Dvorackova, Jana $u Institute of Pathology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.
- 700 1_
- $a Bajsova, Sylva $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.
- 700 1_
- $a Simetka, Ondrej $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 39, č. 1 (2019), s. 421-424
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30591489 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190409153630 $b ABA008
- 999 __
- $a ok $b bmc $g 1391313 $s 1050308
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 1 $d 421-424 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20190405
